CMR Surgical has closed a major funding round exceeding $200 million, combining equity and debt, to fast-track global expansion and innovation of its Versius Surgical Robotic System.
Funding Highlights:
- Backed by existing major investors
- Includes new debt financing from Trinity Capital
- Supports U.S. market entry and launch of Versius Plus
- Strengthens R&D and ongoing clinical trials
Versius, now the second most-used soft tissue surgical robot globally, has powered over 30,000 procedures across 30+ countries, spanning colorectal, gynecology, thoracic, and urology surgeries. The platform’s compact, modular design and broad application make it a leading choice for hospitals worldwide.
CMR is advancing two pioneering trials in paediatric and transoral robotic surgery, showcasing Versius’ adaptability across surgical specialties.
“This funding propels our mission to make robotic-assisted surgery accessible to all,” said CEO Massimiliano Colella.
Follow MEDWIRE.AI for the latest in surgical robotics.
